Donggu Bio & Pharmaceutical Invests Additional 1 Billion Won in Genome & Company
Signed CB Acquisition Agreement
"High Evaluation of Mid- to Long-Term Growth Potential"
Donggu Bio & Pharmaceutical announced on March 10 that it has signed a contract to acquire convertible bonds (CB) worth 1 billion won issued by Genome & Company.
Donggu Bio & Pharmaceutical previously invested approximately 3 billion won in Genome & Company in 2020 and later purchased an additional stake worth about 500 million won on the market, bringing its total investment to about 3.5 billion won to date. A representative from Donggu Bio & Pharmaceutical explained, "We decided to invest based on our high evaluation of Genome & Company's shift in R&D strategy and its mid- to long-term growth potential."
Genome & Company has focused its business on the development of early-stage immune-oncology microbiome therapeutics and research on discovering new targets. Recently, the company has expanded its R&D focus to include the development of antibody and antibody-drug conjugate (ADC) new drugs based on newly discovered targets identified internally.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Chairman Cho Yongjun of Donggu Bio & Pharmaceutical stated, "We plan to continue expanding strategic investments and partnership opportunities with bio-pharmaceutical companies that have global competitiveness in new drug development."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.